Prevail Therapeutics (PRVL) has filed a prospectus for an IPO of 7,353,000 common shares at $16 – 18.
The New York City-based biotech develops AAV-based gene therapies for patients with neurodegenerative disorders who have particular genetic profiles. Lead candidate is PR001 for the treatment of GBA1 mutation-positive Parkinson’s disease (about 7 – 10% of total cases) and neuronopathic Gaucher disease (about 6% of all cases).
2019 Financials (Q1): Operating Expenses: $10.3M (+442.1%); Net Loss: ($9.9M) (-209.4%); Cash Burn: ($12.3M) (-999%).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.